Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11239-020-02208-2 http://scihub22266oqcxt.onion/10.1007/s11239-020-02208-2 32617806!7330540!32617806     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Thrombolysis 2021 ; 51 (2): 293-296 Nephropedia Template TP {{tp|p=32617806|t=2021. Successful use of tPA for thrombolysis in COVID related ARDS: a case series |pdf=|usr=}}{{32617806}} gab.com Text Successful use of tPA for thrombolysis in COVID related ARDS: a case series JO: J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=32617806 #FOAvip We describe successful usage of low dose Tissue plasminogen activator (tPA) (30-50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO(2) > 0.7(on NIV); PiO(2)/FiO(2) ratio < 100 and D-dimer>1000 ng/ml. C.T. Pulmonary Angiography could not be done in these patients due to poor general condition, but 2D echo was normal and none of the patients was in shock. So there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we saw dramatic changes in oxygenation. All patients became off oxygen within 3-7 days and were discharged within 2 weeks. The whole idea was to prevent intubation, since mortality rates are very high in intubated COVID19 patients. tPA is associated with <1% risk of fatal bleed. In this unprecedented pandemic with high mortality rates, thrombolysis could be an effective and safe option in carefully selected critically ill patients of COVID19. Twit Text FOAVip Successful use of tPA for thrombolysis in COVID related ARDS: a case series ????J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=32617806 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32617806 #FOAvip English Wikipedia <ref>{{Cite pmid|32617806}}</ref> Successful use of tPA for thrombolysis in COVID related ARDS: a case series #MMPMID32617806 Goyal A; Saigal S; Niwariya Y; Sharma J; Singh P J Thromb Thrombolysis 2021[Feb]; 51 (2): 293-296 PMID32617806show ga We describe successful usage of low dose Tissue plasminogen activator (tPA) (30-50 mg) in three COVID19 critically ill patients, who were in worsening respiratory failure in-spite of being on therapeutic anticoagulation. All patients had respiratory rate > 40; FiO(2) > 0.7(on NIV); PiO(2)/FiO(2) ratio < 100 and D-dimer>1000 ng/ml. C.T. Pulmonary Angiography could not be done in these patients due to poor general condition, but 2D echo was normal and none of the patients was in shock. So there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we saw dramatic changes in oxygenation. All patients became off oxygen within 3-7 days and were discharged within 2 weeks. The whole idea was to prevent intubation, since mortality rates are very high in intubated COVID19 patients. tPA is associated with <1% risk of fatal bleed. In this unprecedented pandemic with high mortality rates, thrombolysis could be an effective and safe option in carefully selected critically ill patients of COVID19. |COVID-19/*complications/therapy[MESH] |Female[MESH] |Fibrinolytic Agents/administration & dosage/*therapeutic use[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Respiratory Distress Syndrome/*etiology/therapy[MESH] |Thrombolytic Therapy[MESH]Successful use of tPA for thrombolysis in COVID related ARDS: a case s(epmc).pdf DeepDyve Pubget Overpricing